These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9816690)

  • 1. [The impact HMG-CoA reductase inhibitors on the modification of the natural history of coronary artery disease].
    Kaiser SE; de Alcantara ML
    Arq Bras Cardiol; 1998 Aug; 71(2):153-62. PubMed ID: 9816690
    [No Abstract]   [Full Text] [Related]  

  • 2. [WOSCOPS [West of Scotland Coronary Prevention Study]].
    Furutani N; Tada N
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():387-92. PubMed ID: 11347100
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term follow-up of the West of Scotland Coronary Prevention Study.
    Tsubokura M; Kami M
    N Engl J Med; 2008 Jan; 358(2):193-4; author reply 194-5. PubMed ID: 18193526
    [No Abstract]   [Full Text] [Related]  

  • 4. Overlap analysis of the West of Scotland coronary prevention study (WOSCOPS).
    Lim PO; Yee KM
    Circulation; 1999 Aug; 100(6):686. PubMed ID: 10441109
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term follow-up of the West of Scotland Coronary Prevention Study.
    DeFilippis AP; Bansal S; Blumenthal RS
    N Engl J Med; 2008 Jan; 358(2):194; author reply 194-5. PubMed ID: 18193527
    [No Abstract]   [Full Text] [Related]  

  • 6. Summaries for patients. Benefits of lowering cholesterol levels in older patients.
    Ann Intern Med; 2001 May; 134(10):S-4. PubMed ID: 11357858
    [No Abstract]   [Full Text] [Related]  

  • 7. Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease.
    Rackley CE
    Clin Cardiol; 1996 Sep; 19(9):683-9. PubMed ID: 8874986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More on PROSPER.
    Baztán JJ; Hornillos M; Rodríguez-Mañas L
    Lancet; 2003 Mar; 361(9363):1135; author reply 1136. PubMed ID: 12672345
    [No Abstract]   [Full Text] [Related]  

  • 10. HMG-CoA reductase inhibitors reduce stroke risk, total mortality.
    Am J Health Syst Pharm; 1997 Oct; 54(19):2152, 2154. PubMed ID: 9331434
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of childhood hypercholesterolemia with HMG-CoA reductase inhibitors.
    Duplaga BA
    Ann Pharmacother; 1999 Nov; 33(11):1224-7. PubMed ID: 10573325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical inquiries. What is the target for low-density lipoprotein cholesterol in patients with heart disease?
    Stevermer JJ; Meadows SE
    J Fam Pract; 2002 Oct; 51(10):893. PubMed ID: 12401164
    [No Abstract]   [Full Text] [Related]  

  • 14. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.
    Pedersen TR; Tobert JA
    Drug Saf; 1996 Jan; 14(1):11-24. PubMed ID: 8713485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effects of two HMG-CoA reductase inhibitors (lovastatin and pravastatin) on serum lipids and lipoproteins.
    Richter WO; Jacob BG; Schwandt P
    Int J Tissue React; 1991; 13(2):107-10. PubMed ID: 1955291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updated guidelines support even lower cholesterol levels for at-risk patients.
    Levenson D
    Rep Med Guidel Outcomes Res; 2004 Aug; 15(15):1, 6-7. PubMed ID: 15320342
    [No Abstract]   [Full Text] [Related]  

  • 17. Recent developments in coronary heart disease prevention: the Scandinavian and west of Scotland studies.
    Elam MB; Cushman W; Applegate WB; Heimberg M
    Tenn Med; 1997 May; 90(5):189-92. PubMed ID: 9130876
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term follow-up of the West of Scotland Coronary Prevention Study.
    Ford I; Murray H; Packard CJ; Shepherd J; Macfarlane PW; Cobbe SM;
    N Engl J Med; 2007 Oct; 357(15):1477-86. PubMed ID: 17928595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pravastatin and the development of diabetes mellitus. Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study].
    Comaschi MA; Menozzi F
    Ital Heart J Suppl; 2001 May; 2(5):556-8. PubMed ID: 11388336
    [No Abstract]   [Full Text] [Related]  

  • 20. Statin fails to meet expectations.
    Traynor K
    Am J Health Syst Pharm; 2003 Feb; 60(3):233. PubMed ID: 12613230
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.